AtriCure (NASDAQ:ATRC) Reaches New 52-Week High After Analyst Upgrade

AtriCure, Inc. (NASDAQ:ATRC)’s stock price hit a new 52-week high on Monday after BTIG Research raised their price target on the stock from $45.00 to $55.00. BTIG Research currently has a buy rating on the stock. AtriCure traded as high as $49.58 and last traded at $49.30, with a volume of 15650 shares traded. The stock had previously closed at $48.98.

ATRC has been the topic of a number of other research reports. Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research raised AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Citigroup restated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Canaccord Genuity Group lifted their target price on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average target price of $48.62.

Insider Buying and Selling

In other news, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the transaction, the director owned 22,809 shares of the company’s stock, valued at $884,989.20. This represents a 13.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider directly owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,246 shares of company stock worth $1,691,895 in the last three months. Insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On AtriCure

Several hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in shares of AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock worth $2,700,000 after buying an additional 837 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after acquiring an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after acquiring an additional 8,956 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after acquiring an additional 87,553 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of AtriCure in the 1st quarter valued at about $158,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Trading Up 0.8%

The stock has a market cap of $2.51 billion, a P/E ratio of 235.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The stock has a 50-day moving average price of $35.83 and a 200-day moving average price of $31.81.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The company had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure, Inc. will post 0.2 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.